MCMCB Pro
G2113

G2113Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity

HCPCSActiveBETOS Z2

G2113 is a HCPCS Level II code for patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity. It belongs to the Procedures and Professional Services (Temporary) section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusM

Measurement code. Used for reporting purposes only; never paid.

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

The CMS record for G2113

Long descriptor
Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity

The official wording. This is what the code means.

Short descriptor
Pred>5 mg >6m, no chg da

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2020

When CMS introduced the code.

BETOS
Z2

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
00 — Not priced by Part B

Service not separately priced by Part B — not covered, bundled into another service, or used by Part A only.

Codes adjacent to G2113

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If G2113 is not quite right, the correct code is very often within a few positions of it.

  • G2104Eye imaging validated to match diagnosis from seven standard field stereoscopic photos results documented and reviewedterminated
  • G2105Patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period
  • G2106Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
  • G2107Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and an advanced illness diagnosis during the measurement period or the year prior to the measurement period
  • G2108Patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement periodterminated
  • G2109Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement periodterminated
  • G2110Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement periodterminated
  • G2112Patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months
  • G2114Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement periodterminated
  • G2115Patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
  • G2116Patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and an advanced illness diagnosis during the measurement period or the year prior to the measurement period
  • G2117Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement periodterminated
  • G2118Patients 81 years of age and older with at least one claim/encounter for frailty during the measurement period
  • G2119Within the past 2 years, calcium and/or vitamin d optimization has been ordered or performedterminated
  • G2120Within the past 2 years, calcium and/or vitamin d optimization has not been ordered or performedterminated
  • G2121Depression, anxiety, apathy, and psychosis assessed

Questions about G2113

What is HCPCS code G2113?

G2113 is a HCPCS Level II code for patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity. It sits in the Procedures and Professional Services (Temporary) section.

Does Medicare cover G2113?

The CMS HCPCS file marks G2113 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

How is G2113 paid under the physician fee schedule?

G2113 carries PFS status code M. Measurement code. Used for reporting purposes only; never paid.

HCPCS Level II2026Q3-Jul· effective July 1, 2026